SMS Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
SMSPHARMA
Pharmaceuticals
Screen SMS Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹335.70
▲
9.45 (2.90%)
Share Price BSE
₹335.75
▲
10.35 (3.18%)
Market Cap
₹2,935.52 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.98
EPS (TTM)
₹8.16
Dividend Yield
0.12%
Debt to Equity
0.50
52W High
₹335.70
52W Low
₹183.25
Operating Margin
16.00%
Profit Margin
8.00%
Revenue (TTM)
₹250.00
EBITDA
₹42.00
Net Income
₹20.00
Total Assets
₹1,153.00
Total Equity
₹640.00
SMS Pharmaceuticals Share Price History - Stock Screener Chart
Screen SMSPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
SMS Pharmaceuticals Company Profile - Fundamental Screener
Screen SMS Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SMSPHARMA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE812G01025
SMS Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SMSPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,153 | 1,034 | 880 | 860 | 812 | 608 | 559 | 503 | 493 | 656 |
| Current Assets | 555 | 534 | 411 | 377 | 309 | 219 | 208 | 169 | 157 | 248 |
| Fixed Assets | 533 | 437 | 412 | 438 | 457 | 281 | 281 | 279 | 291 | 370 |
| Liabilities | ||||||||||
| Total Liabilities | 1,153 | 1,034 | 880 | 860 | 812 | 608 | 559 | 503 | 493 | 656 |
| Current Liabilities | 189 | 166 | 164 | 193 | 206 | 115 | 94 | 97 | 91 | 162 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 640 | 536 | 461 | 470 | 411 | 348 | 322 | 285 | 255 | 294 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves & Surplus | 615 | 499 | 452 | 462 | 402 | 340 | 314 | 276 | 246 | 285 |
Screen SMSPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 250 | 197 | 244 | 248 | 166 | 198 | 176 | 151 | 136 | 167 | 163 | 61 | 65 | 160 | 151 |
| Expenses | 207 | 157 | 194 | 212 | 131 | 165 | 140 | 126 | 109 | 139 | 133 | 65 | 65 | 146 | 130 |
| EBITDA | 42 | 40 | 50 | 35 | 35 | 33 | 35 | 25 | 27 | 29 | 31 | -4 | 0 | 14 | 21 |
| Operating Profit % | 16.00% | 20.00% | 20.00% | 14.00% | 20.00% | 16.00% | 19.00% | 16.00% | 19.00% | 17.00% | 18.00% | -7.00% | -1.00% | 9.00% | 12.00% |
| Depreciation | 9 | 10 | 10 | 8 | 8 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Interest | 5 | 6 | 6 | 6 | 5 | 5 | 4 | 6 | 6 | 6 | 6 | 4 | 5 | 5 | 6 |
| Profit Before Tax | 29 | 24 | 34 | 22 | 22 | 20 | 22 | 11 | 13 | 15 | 17 | -16 | -13 | 1 | 7 |
| Tax | 8 | 4 | 9 | 5 | 5 | 5 | 4 | 4 | 3 | 3 | 5 | -23 | 0 | 3 | 3 |
| Net Profit | 20 | 21 | 25 | 17 | 17 | 14 | 18 | 6 | 9 | 12 | 12 | 6 | -13 | -2 | 4 |
| EPS | 2.40 | 2.31 | 2.84 | 2.04 | 1.95 | 1.67 | 2.15 | 0.73 | 1.10 | 1.39 | 1.36 | 0.73 | -1.51 | -0.24 | 0.44 |
SMS Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SMSPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 82 | 50 | 23 | 45 | 90 | 40 | 50 | 32 | 74 | 61 |
| Investing Activities | -123 | -52 | -30 | -27 | -152 | -43 | -35 | -17 | -39 | -97 |
| Financing Activities | 47 | 31 | -32 | -12 | 92 | -2 | -13 | -15 | -33 | 27 |
| Net Cash Flow | 5 | 29 | -39 | 6 | 31 | -5 | 2 | 0 | 1 | -9 |
Screen SMSPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.07% | 66.26% | 66.26% | 64.67% | 64.67% | 64.67% | 64.67% | 64.32% |
| FII Holding | 0.28% | 0.03% | 0.08% | 0.31% | 0.52% | 0.17% | 0.17% | 0.59% |
| DII Holding | 2.88% | 3.03% | 2.43% | 2.55% | 2.55% | 2.13% | 1.98% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 24.02% | 25.89% | 26.35% | 27.38% | 27.04% | 27.81% | 27.93% | 29.22% |
| Other Holding | 4.76% | 4.78% | 4.87% | 5.09% | 5.23% | 5.22% | 5.25% | 5.88% |
| Shareholder Count | 34,157 | 33,652 | 35,332 | 34,973 | 33,136 | 31,780 | 30,140 | 25,341 |
SMS Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen SMSPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.40 | 0.13% |
| 2024-March | ₹0.40 | 0.19% |
| 2023-March | ₹0.30 | 0.17% |
| 2022-March | ₹0.30 | 0.53% |
| 2021-March | ₹0.30 | 0.32% |
| 2020-March | ₹0.25 | 0.20% |
| 2019-March | ₹0.25 | 0.93% |
| 2018-March | ₹0.25 | 0.40% |
| 2017-March | ₹0.20 | 0.27% |
SMS Pharmaceuticals Index Membership - Market Screener Classification
Screen SMSPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
SMS Pharmaceuticals Market Events Screener - Corporate Actions
Screen SMSPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.40 /share | 8.19% | ||
| Dividend | ₹ 0.30 /share | 6.46% | ||
| Dividend | ₹ 0.30 /share | 43.96% | ||
| Dividend | ₹ 0.30 /share | -5.91% | ||
| Dividend | ₹ 0.40 /share | 75.63% | ||
| Annual General Meeting | NA | 12.37% | ||
| Annual General Meeting | NA | 12.38% | ||
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | 0.91% |
| 2025-08-09 | 2025-08-09 | Quarterly Result Announcement | NA | -2.17% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 3.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -2.50% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 3.84% |
| 2024-03-06 | 2024-03-06 | Extraordinary General Meeting | NA | 24.21% |
SMS Pharmaceuticals Competitors Screener - Peer Comparison
Screen SMSPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
SMS Pharmaceuticals Company Announcements - News Screener
Screen SMSPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Closure of Trading Window | View |
| 2025-12-31 | Announcement Under Regulation 30 - Investments In Subsidiary Company By Way Of Subscription Towards Rights Issue | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2025-11-11 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-11-11 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-08 | Statement Of Deviation Or Variation For The Quarter Ended September 30 2025 | View |
| 2025-11-08 | Financial Results For The Quarter Ended 30Th September 2025 | View |
| 2025-11-08 | Board Meeting Outcome for Outcome Of Board Meeting For Financial Results | View |
| 2025-11-07 | Intimation Of Receipt Of Trading Approval From Stock Exchanges | View |
| 2025-11-06 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-11-06 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |